Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
08:30am, Tuesday, 12'th Mar 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
05:00pm, Friday, 16'th Feb 2024
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidia
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
04:20pm, Monday, 04'th Dec 2023
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on
Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript
10:54pm, Tuesday, 14'th Nov 2023
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2023 Results Conference Call November 14, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CF
PAVmed Provides Business Update and Third Quarter Financial Results
05:43pm, Tuesday, 14'th Nov 2023
Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and web
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
05:40pm, Monday, 13'th Nov 2023
NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiar
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
09:00am, Thursday, 09'th Nov 2023
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs Lucid Diagnostics Investor Day, where
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
09:18am, Thursday, 02'nd Nov 2023
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-s
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
09:00am, Thursday, 24'th Aug 2023
EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or
Lucid Diagnostics Inc. (LUCD) Q2 2023 Earnings Call Transcript
12:38pm, Tuesday, 15'th Aug 2023
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conf
Lucid Diagnostics Inc. (LUCD) Q1 2023 Earnings Call Transcript
07:39pm, Tuesday, 16'th May 2023
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2023 Results Conference Call May 16, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Confe
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
09:45pm, Monday, 17'th Apr 2023
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiar
Lucid to cut 1,300 workers amid signs of flagging demand for its EVs
04:41pm, Tuesday, 28'th Mar 2023
Lucid CEO Peter Rawlinson said the job cuts will hit "nearly every organization and level, including executives."
Lucid Diagnostics Inc. (LUCD) Q4 2022 Earnings Call Transcript
02:18pm, Tuesday, 14'th Mar 2023
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2022 Earnings Conference Call March 14, 2023 8:30 AM ET Company Participants Michael Parks - Vice President, Investor Relations Dr. Lishan Aklog - Chairman and
Lucid Diagnostics Inc. (LUCD) Q3 2022 Earnings Call Transcript
09:50pm, Monday, 14'th Nov 2022
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chi
